Fundraising and Allocation - The total amount raised from the subscription is approximately HKD 326.9 million, with a net amount of about HKD 326.5 million after expenses, equivalent to a net issue price of approximately HKD 3.106 per share[6]. - 30% of the net proceeds (approximately HKD 98.0 million) will be allocated for the development and commercialization of the targeted lung denervation system (TLD system), covering technology iteration, clinical trials, and marketing[6]. - 35% of the net proceeds (approximately HKD 114.2 million) will fund the key technology development for the natural orifice flexible surgical robot, with clinical trials expected to be completed by 2029[6]. - 20% of the net proceeds (approximately HKD 65.3 million) will be used to establish an overseas headquarters in Ireland, focusing on obtaining overseas regulatory approvals and commercializing core products[6]. - 15% of the net proceeds (approximately HKD 49.0 million) will be allocated for the company's working capital and other general corporate purposes, expected to be fully utilized by 2028[6]. Regulatory and Operational Updates - The company is currently in the approval process for necessary consents related to the subscription agreement, with submissions made to the relevant regulatory authorities in China[4]. - The company plans to provide further announcements regarding the completion of the subscription at an appropriate time[5]. - The overseas headquarters will integrate and coordinate existing overseas operations, enhancing management of international business activities[6]. - The company aims to commercialize the BroncAblate® system in China by the first half of 2025, following approval from the National Medical Products Administration (NMPA)[6]. Executive Compensation - The company has not granted restricted share units to any of the top five highest-paid individuals for the year ending December 31, 2024, except for the executive director and CEO Xu Hong[7].
堃博医疗(02216) - 2025 - 年度业绩